> top > projects > sentences > docs > PubMed:20215531 > annotations
sentences Home  

PubMed:20215531 JSONTXT 9 Projects

Annnotations TAB TSV DIC JSON TextAE Lectin_function IAV-Glycan

Id Subject Object Predicate Lexical cue
TextSentencer_T1 0-77 Sentence denotes Germline BRCA mutations denote a clinicopathologic subset of prostate cancer.
T1 0-77 Sentence denotes Germline BRCA mutations denote a clinicopathologic subset of prostate cancer.
TextSentencer_T2 78-86 Sentence denotes PURPOSE:
T2 78-86 Sentence denotes PURPOSE:
TextSentencer_T3 87-241 Sentence denotes Increased prostate cancer risk has been reported for BRCA mutation carriers, but BRCA-associated clinicopathologic features have not been clearly defined.
T3 87-241 Sentence denotes Increased prostate cancer risk has been reported for BRCA mutation carriers, but BRCA-associated clinicopathologic features have not been clearly defined.
TextSentencer_T4 242-262 Sentence denotes EXPERIMENTAL DESIGN:
T4 242-262 Sentence denotes EXPERIMENTAL DESIGN:
TextSentencer_T5 263-518 Sentence denotes We determined BRCA mutation prevalence in 832 Ashkenazi Jewish men diagnosed with localized prostate cancer between 1988 and 2007 and 454 Ashkenazi Jewish controls and compared clinical outcome measures among 26 BRCA mutation carriers and 806 noncarriers.
T5 263-518 Sentence denotes We determined BRCA mutation prevalence in 832 Ashkenazi Jewish men diagnosed with localized prostate cancer between 1988 and 2007 and 454 Ashkenazi Jewish controls and compared clinical outcome measures among 26 BRCA mutation carriers and 806 noncarriers.
TextSentencer_T6 519-728 Sentence denotes Kruskal-Wallis tests were used to compare age of diagnosis and Gleason score, and logistic regression models were used to determine associations between carrier status, prostate cancer risk, and Gleason score.
T6 519-728 Sentence denotes Kruskal-Wallis tests were used to compare age of diagnosis and Gleason score, and logistic regression models were used to determine associations between carrier status, prostate cancer risk, and Gleason score.
TextSentencer_T7 729-825 Sentence denotes Hazard ratios (HR) for clinical end points were estimated using Cox proportional hazards models.
T7 729-825 Sentence denotes Hazard ratios (HR) for clinical end points were estimated using Cox proportional hazards models.
TextSentencer_T8 826-1136 Sentence denotes RESULTS: BRCA2 mutations were associated with a 3-fold risk of prostate cancer [odds ratio, 3.18; 95% confidence interval (95% CI), 1.52-6.66; P = 0.002] and presented with more poorly differentiated (Gleason score > or =7) tumors (85% versus 57%; P = 0.0002) compared with non-BRCA-associated prostate cancer.
T8 826-1136 Sentence denotes RESULTS: BRCA2 mutations were associated with a 3-fold risk of prostate cancer [odds ratio, 3.18; 95% confidence interval (95% CI), 1.52-6.66; P = 0.002] and presented with more poorly differentiated (Gleason score > or =7) tumors (85% versus 57%; P = 0.0002) compared with non-BRCA-associated prostate cancer.
TextSentencer_T9 1137-1181 Sentence denotes BRCA1 mutations conferred no increased risk.
T9 1137-1181 Sentence denotes BRCA1 mutations conferred no increased risk.
TextSentencer_T10 1182-1567 Sentence denotes After 7,254 person-years of follow-up, and adjusting for clinical stage, prostate-specific antigen, Gleason score, and treatment, BRCA2 and BRCA1 mutation carriers had a higher risk of recurrence [HR (95% CI), 2.41 (1.23-4.75) and 4.32 (1.31-13.62), respectively] and prostate cancer-specific death [HR (95% CI), 5.48 (2.03-14.79) and 5.16 (1.09-24.53), respectively] than noncarriers.
T10 1182-1567 Sentence denotes After 7,254 person-years of follow-up, and adjusting for clinical stage, prostate-specific antigen, Gleason score, and treatment, BRCA2 and BRCA1 mutation carriers had a higher risk of recurrence [HR (95% CI), 2.41 (1.23-4.75) and 4.32 (1.31-13.62), respectively] and prostate cancer-specific death [HR (95% CI), 5.48 (2.03-14.79) and 5.16 (1.09-24.53), respectively] than noncarriers.
TextSentencer_T11 1568-1761 Sentence denotes CONCLUSIONS: BRCA2 mutation carriers had an increased risk of prostate cancer and a higher histologic grade, and BRCA1 or BRCA2 mutations were associated with a more aggressive clinical course.
T11 1568-1761 Sentence denotes CONCLUSIONS: BRCA2 mutation carriers had an increased risk of prostate cancer and a higher histologic grade, and BRCA1 or BRCA2 mutations were associated with a more aggressive clinical course.
TextSentencer_T12 1762-1877 Sentence denotes These results may have implications for tailoring clinical management of this subset of hereditary prostate cancer.
T12 1762-1877 Sentence denotes These results may have implications for tailoring clinical management of this subset of hereditary prostate cancer.